Silymarin treatment and reduction of liver enzyme levels in non-alcoholic fatty liver disease: a case report
Open Access
- 6 April 2023
- journal article
- research article
- Published by BioExcel in Drugs in Context
- Vol. 12, 1-5
Abstract
This case report examines silymarin treatment prescribed to a patient with overweight and non-alcoholic fatty liver disease, with an attempt to manage the increased liver enzyme activity levels.Keywords
This publication has 9 references indexed in Scilit:
- Non-alcoholic fatty liver diseaseThe Lancet, 2021
- Expert Opinion on the Management of Non-Alcoholic Fatty Liver Disease (NAFLD) in the Middle East with a Focus on the Use of SilymarinGastroenterology Insights, 2021
- Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysisNutrition, 2021
- Nonalcoholic Fatty Liver Disease and Recent Guideline UpdatesClinical Liver Disease, 2021
- Silymarin as Supportive Treatment in Liver Diseases: A Narrative ReviewAdvances in Therapy, 2020
- A Randomized Trial of Silymarin for the Treatment of Nonalcoholic SteatohepatitisClinical Gastroenterology and Hepatology, 2017
- Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial.2014
- Silymarin in non alcoholic fatty liver diseaseWorld Journal of Hepatology, 2013
- Nonalcoholic Fatty Liver Disease: A Clinical Approach and ReviewCanadian Journal of Gastroenterology and Hepatology, 2006